Page last updated: 2024-10-30

leflunomide and Adjuvant Arthritis

leflunomide has been researched along with Adjuvant Arthritis in 25 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Research Excerpts

ExcerptRelevanceReference
"These results demonstrate that topically applied leflunomide can be delivered effectively and deposited as teriflunomide in an arthritic joint, possibly allowing better compliance in rheumatoid arthritis patients by avoiding leflunomide's side effects."7.83Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model. ( Bae, J; Park, JW, 2016)
"To investigate the effects of leflunomide (LEF) on modulating interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor- alpha (TNF-alpha) production induced by lipopolysaccharide (LPS) in peritoneal macrophages (PMphi) in adjuvant arthritis rats and elucidate the possible mechanisms of antiinflammatory and antirheumatoid effects of LEF."7.71Dynamic effects of leflunomide on IL-1, IL-6, and TNF-alpha activity produced from peritoneal macrophages in adjuvant arthritis rats. ( Li, WD; Lin, ZB; Ran, GX; Teng, HL, 2002)
"To observe the effects of leflunomide (LEF), an isoxazole immunomodulatory agent and its active metabolite, A771726, on the production and mRNA expression of TNF-alpha in peritoneal macrophages and synovial cells with adjuvant arthritis rats and to further investigate the immunosuppression effects of leflunomide and its mechanisms."7.71[Effects of leflunomide and its active metabolite on the production and mRNA expression of TNF-alpha in peritoneal macrophages and synovial cells with adjuvant arthritis in rats]. ( Li, WD; Lin, ZB, 2002)
"Leflunomide is a low-molecular-weight compound that is widely used in the treatment of rheumatoid arthritis."3.85The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1. ( Cho, ML; Jhun, JY; Kim, EK; Lee, HJ; Lee, WS; Min, JK; Moon, SJ; Park, SH, 2017)
"These results demonstrate that topically applied leflunomide can be delivered effectively and deposited as teriflunomide in an arthritic joint, possibly allowing better compliance in rheumatoid arthritis patients by avoiding leflunomide's side effects."3.83Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model. ( Bae, J; Park, JW, 2016)
"Nimesulide is a COX-2 inhibitor used for symptomatic relief of rheumatoid arthritis."3.80Nimesulide improves the symptomatic and disease modifying effects of leflunomide in collagen induced arthritis. ( Abdel-Naim, AB; Al-Abbasi, FA; Al-Abd, AM; El-Eraky, WI; Khalifa, AE; Nagy, AA; Nofal, SM; Williams, RO, 2014)
"Iguratimod, a novel disease-modifying antirheumatic drug, which is now used in clinics in China and Japan, has been confirmed as a highly efficacious and safe drug for rheumatoid arthritis therapy."3.79A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. ( Gu, Y; Jin, B; Liu, W; Luo, Q; Qian, C; Shen, Y; Sun, Y; Tao, F; Wu, X; Xu, Q, 2013)
"To investigate the effects of leflunomide (LEF) on modulating interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor- alpha (TNF-alpha) production induced by lipopolysaccharide (LPS) in peritoneal macrophages (PMphi) in adjuvant arthritis rats and elucidate the possible mechanisms of antiinflammatory and antirheumatoid effects of LEF."3.71Dynamic effects of leflunomide on IL-1, IL-6, and TNF-alpha activity produced from peritoneal macrophages in adjuvant arthritis rats. ( Li, WD; Lin, ZB; Ran, GX; Teng, HL, 2002)
"To observe the effects of leflunomide (LEF), an isoxazole immunomodulatory agent and its active metabolite, A771726, on the production and mRNA expression of TNF-alpha in peritoneal macrophages and synovial cells with adjuvant arthritis rats and to further investigate the immunosuppression effects of leflunomide and its mechanisms."3.71[Effects of leflunomide and its active metabolite on the production and mRNA expression of TNF-alpha in peritoneal macrophages and synovial cells with adjuvant arthritis in rats]. ( Li, WD; Lin, ZB, 2002)
" This study compared groups treated with high-dose methotrexate (MTX)/leflunomide (LEF) and CP-25 combined with low-dose MTX/LEF in an adjuvant-induced arthritis (AA) rat model and investigated possible mechanisms."1.51CP-25 combined with MTX/ LEF ameliorates the progression of adjuvant-induced arthritis by the inhibition on GRK2 translocation. ( Chang, Y; Jia, X; Wang, C; Wei, W; Wu, Y; Yang, X; Zhang, L; Zhao, Y, 2019)
" From the day of arthritis onset, rats were treated daily by gavage with leflunomide (Lef) or ART at a dosage of 10 mg/kg/d or 5 mg/kg/d, respectively, for 16 days."1.39Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway. ( Chen, G; Huang, H; Li, C; Li, Y; Lin, S; Lin, W; Liu, P; Shen, W; Shen, X; Wang, S; Wang, Y; Zhou, C, 2013)
" Drug studies were performed, using a 4-day dosing schedule, on optimal DTH elicited on day 10, suboptimal DTH elicited on day 15, and AA (day 16)."1.28Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis. ( Hambleton, P; McMahon, S, 1990)
"), dosed for 8 or 16 days beginning with the day of adjuvant administration, significantly reduced edema, fibrinogen levels, and erythrocyte sedimentation rates (ESR) 42 days later."1.27Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis. ( Buyniski, JP; Gylys, JA; Pasternak, RD; Siminoff, P; Wadopian, NS; Wright, RN, 1987)

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19903 (12.00)18.7374
1990's3 (12.00)18.2507
2000's4 (16.00)29.6817
2010's14 (56.00)24.3611
2020's1 (4.00)2.80

Authors

AuthorsStudies
Kuo, EA1
Hambleton, PT1
Kay, DP1
Evans, PL1
Matharu, SS1
Little, E1
McDowall, N1
Jones, CB1
Hedgecock, CJ1
Yea, CM1
Chan, AW1
Hairsine, PW1
Ager, IR1
Tully, WR1
Williamson, RA1
Westwood, R1
Manolios, N1
Hou, G1
El-Sheikh, SMA1
Abd El-Alim, AEF1
Galal, AAA1
El-Sayed, RG1
El-Naseery, NI1
Liang, C1
Li, J2
Lu, C1
Xie, D1
Liu, J1
Zhong, C1
Wu, X2
Dai, R1
Zhang, H1
Guan, D1
Guo, B1
He, B1
Li, F1
He, X1
Zhang, W1
Zhang, BT1
Zhang, G1
Lu, A1
Yang, X1
Zhao, Y1
Jia, X1
Wang, C1
Wu, Y1
Zhang, L1
Chang, Y1
Wei, W1
Luo, Q1
Sun, Y1
Liu, W1
Qian, C1
Jin, B1
Tao, F1
Gu, Y1
Shen, Y1
Xu, Q1
Al-Abd, AM1
Al-Abbasi, FA1
Nofal, SM1
Khalifa, AE1
Williams, RO1
El-Eraky, WI1
Nagy, AA1
Abdel-Naim, AB1
Bae, J1
Park, JW1
Gowayed, MA1
Refaat, R1
Ahmed, WM1
El-Abhar, HS1
El-Setouhy, DA1
Abdelmalak, NS1
Anis, SE1
Louis, D1
Gao, HY1
Luo, J1
Li, XF1
Lv, Q1
Wen, HY1
Song, QZ1
Zhao, WP1
Zhao, XC1
Zhang, TT1
Zhang, SY1
Zhi, JM1
Moon, SJ1
Kim, EK1
Jhun, JY1
Lee, HJ1
Lee, WS1
Park, SH1
Cho, ML1
Min, JK1
Wang, TY1
Li, CY1
Jin, Y1
Lü, XW1
Wang, XH1
Zhou, Q1
Yamaguchi, T1
Kakefuda, R1
Tanimoto, A1
Watanabe, Y1
Tajima, N1
Li, Y2
Wang, S1
Wang, Y1
Zhou, C1
Chen, G1
Shen, W1
Li, C1
Lin, W1
Lin, S1
Huang, H1
Liu, P1
Shen, X1
Yao, Y1
Ding, CZ1
Fang, Y1
Li, WD2
Ran, GX1
Teng, HL1
Lin, ZB2
Wei, YH1
Qiang, CJ1
Oliushin, IuA1
Smith-Oliver, T1
Noel, LS1
Stimpson, SS1
Yarnall, DP1
Connolly, KM1
Hambleton, P1
McMahon, S1
Hirschelmann, R1
Schade, R1
Pasternak, RD1
Wadopian, NS1
Wright, RN1
Siminoff, P1
Gylys, JA1
Buyniski, JP1
Bartlett, RR1
Schleyerbach, R1

Reviews

1 review available for leflunomide and Adjuvant Arthritis

ArticleYear
[Basic therapy of rheumatoid arthritis with leflunomide (review)].
    Terapevticheskii arkhiv, 2004, Volume: 76, Issue:10

    Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Ma

2004

Other Studies

24 other studies available for leflunomide and Adjuvant Arthritis

ArticleYear
Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds.
    Journal of medicinal chemistry, 1996, Nov-08, Volume: 39, Issue:23

    Topics: Acrylamides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Dihydroorota

1996
Anti-inflammatory Effects of First-line Anti-arthritic Drugs on T-cell Activation.
    Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2023, Volume: 21, Issue:3

    Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Cytokines; Leflunomide; Mice; Th1 Cells;

2023
Anti-arthritic effect of β-caryophyllene and its ameliorative role on methotrexate and/or leflunomide-induced side effects in arthritic rats.
    Life sciences, 2019, Sep-15, Volume: 233

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Arthritis, Experi

2019
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis.
    Nature communications, 2019, 10-08, Volume: 10, Issue:1

    Topics: Acriflavine; Adult; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Aryl Hydrocarbon Recept

2019
CP-25 combined with MTX/ LEF ameliorates the progression of adjuvant-induced arthritis by the inhibition on GRK2 translocation.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 110

    Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Cells, Cultured; Disease Progression; Drug T

2019
A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.
    Journal of immunology (Baltimore, Md. : 1950), 2013, Nov-15, Volume: 191, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antirheumatic Agents; Arthritis, Experimental; Arthri

2013
Nimesulide improves the symptomatic and disease modifying effects of leflunomide in collagen induced arthritis.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Drug Synergism; Drug

2014
Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
    Drug development and industrial pharmacy, 2016, Volume: 42, Issue:2

    Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental

2016
Effect of galantamine on adjuvant-induced arthritis in rats.
    European journal of pharmacology, 2015, Oct-05, Volume: 764

    Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Biomarkers; Dose-Response Relationship,

2015
Leflunomide biodegradable microspheres intended for intra-articular administration: Development, anti-inflammatory activity and histopathological studies.
    International journal of pharmaceutics, 2015, Nov-30, Volume: 495, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Experimental; Chemistry, Pharmac

2015
Changes in focal adhesion kinase expression in rats with collagen-induced arthritis and efficacy of intervention with disease modifying anti-rheumatic drugs alone or in combination.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:12

    Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Collagen Type II; Cyclophosphamide; Drug The

2015
The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
    Journal of translational medicine, 2017, 02-13, Volume: 15, Issue:1

    Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid

2017
Leflunomide induces immunosuppression in collagen-induced arthritis rats by upregulating CD4+CD25+ regulatory T cells.
    Canadian journal of physiology and pharmacology, 2010, Volume: 88, Issue:1

    Topics: Adjuvants, Immunologic; Animals; Arthritis, Experimental; Cattle; CD4 Antigens; Immunosuppressive Ag

2010
Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2012, Volume: 61, Issue:5

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Col

2012
Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway.
    Translational research : the journal of laboratory and clinical medicine, 2013, Volume: 161, Issue:2

    Topics: Animals; Antimalarials; Antirheumatic Agents; Artemisinins; Artesunate; Arthritis, Experimental; Art

2013
Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats.
    Rheumatology international, 2013, Volume: 33, Issue:7

    Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Bone and Bones; Cell Survival; Cells, Cu

2013
Dynamic effects of leflunomide on IL-1, IL-6, and TNF-alpha activity produced from peritoneal macrophages in adjuvant arthritis rats.
    Acta pharmacologica Sinica, 2002, Volume: 23, Issue:8

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Female; Interleukin-1; In

2002
[Effects of leflunomide and its active metabolite on the production and mRNA expression of TNF-alpha in peritoneal macrophages and synovial cells with adjuvant arthritis in rats].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2002, Volume: 37, Issue:10

    Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; C

2002
Effects and mechanisms of FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor, on adjuvant arthritis in rats.
    International immunopharmacology, 2004, Dec-15, Volume: 4, Issue:13

    Topics: Animals; Arthritis, Experimental; Body Weight; Cell Proliferation; China; Disease Models, Animal; Do

2004
Elevated levels of TNF in the joints of adjuvant arthritic rats.
    Cytokine, 1993, Volume: 5, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Biological Assay; Cells,

1993
Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis.
    Agents and actions, 1990, Volume: 29, Issue:3-4

    Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Bacterial; Art

1990
6-Sulfanilamidoindazole arthritis in rats: influence of the new anti-inflammatory agent CGP 28237 and of the immunomodulating compound HWA 486 on degree of arthritis and on acute phase reaction.
    Die Pharmazie, 1988, Volume: 43, Issue:1

    Topics: Acute-Phase Reaction; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Experi

1988
Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis.
    Agents and actions, 1987, Volume: 21, Issue:3-4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Experimental; Cyclosporins;

1987
Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat.
    International journal of immunopharmacology, 1985, Volume: 7, Issue:1

    Topics: Animals; Anti-Inflammatory Agents; Arthritis; Arthritis, Experimental; Cyclophosphamide; Immunosuppr

1985